Get the Stockscreener App
1.41
7.63%
0.10
After Hours:
1.48
0.07
+4.96%
Filana Therapeutics Inc stock is traded at $1.41, with a volume of 698.81K.
It is up +7.63% in the last 24 hours and down -12.42% over the past month.
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.
See More
Previous Close:
$1.31
Open:
$1.36
24h Volume:
698.81K
Relative Volume:
2.20
Market Cap:
$68.11M
Revenue:
-
Net Income/Loss:
$-90.97M
P/E Ratio:
-0.7485
EPS:
-1.8837
Net Cash Flow:
$-32.83M
1W Performance:
+17.50%
1M Performance:
-12.42%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$1.36
$1.53
1-Week Range:
$1.19
$1.53
52-Week Range:
$1.16
$2.0901
Filana Therapeutics Inc Stock (FLNA) Company Profile
Name
Filana Therapeutics Inc
Sector
Industry
Phone
512-501-2444
Address
6801 N CAPITAL OF TEXAS HIGHWAY, AUSTIN
Compare FLNA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FLNA
Filana Therapeutics Inc
|
1.41 | 63.28M | 0 | -90.97M | -32.83M | -1.8837 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Filana Therapeutics Inc Stock (FLNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-26-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-08-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-01-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-16-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jul-15-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jul-07-21 | Reiterated | Maxim Group | Buy |
| Apr-27-21 | Initiated | B. Riley Securities | Buy |
| Feb-16-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-23-20 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-23-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-18-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-15-20 | Downgrade | Maxim Group | Buy → Hold |
| Jan-10-20 | Reiterated | Maxim Group | Buy |
View All
Filana Therapeutics Inc Stock (FLNA) Latest News
Filana Therapeutics (FLNA) Posts Modest Gains Amid Broader Biotech ResilienceExpert Breakout Alerts - Newser
FLNA Should I Buy - Intellectia AI
Filana Therapeutics (FLNA) Stock: Up +0.80%, Key Resistance at $1.32 2026-05-21Community Trade Ideas - Newser
FLNA Price Today: Filana Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC
FLNA Stock Price, Quote & Chart | FILANA THERAPEUTICS INC (NASDAQ:FLNA) - ChartMill
MSN Money - MSN
Filana Therapeutics 1Q Loss/Shr 21c >FLNA - Moomoo
Filana Therapeutics (NASDAQ: FLNA) trims Q1 2026 loss, pivots simufilam to TSC epilepsy - Stock Titan
Filana Therapeutics Releases Q1 2026 Financial Results and Business Update on May 7, 2026 - geneonline.com
Filana Therapeutics Reports Q1 2026 Financial Results and Business Update - The Manila Times
Cost cuts shrink Filana Therapeutics (NASDAQ: FLNA) Q1 2026 net loss - Stock Titan
Biotech with $86.6M cash says FDA hold keeps epilepsy trial on hold - Stock Titan
Cassava Sciences | 8-K: Current report - Moomoo
At a Madrid epilepsy meeting, Filana detailed why it’s testing simufilam - Stock Titan
Filana Therapeutics Presents TSC-Related Epilepsy Program at Eilat XVIII - GlobeNewswire
MSN - MSN
[ARS] FILANA THERAPEUTICS, INC. SEC Filing - Stock Titan
Filana Therapeutics (FLNA) details 2026 meeting and equity plan vote - Stock Titan
Filana Therapeutics (FLNA) director O’Donnell to leave board after 2026 meeting - Stock Titan
How does Filana Therapeutics (FLNA) make money? (Market Focus) 2026-04-27Senior Analyst Forecasts - newser.com
Cassava Sciences (FLNA) Stock Price, News & Analysis $FLNA - MarketBeat
FLNA Filana Therapeutics posts narrower than expected Q3 2025 loss, shares edge higher in today’s trading.Trade Idea Marketplace - Newser
Is Filana Therapeutics (FLNA) stock appealing for long-term investors (Slight Rise) 2026-04-20Continuation Pattern - Xã Châu Thành
Filana Therapeutics Inc Stock (FLNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):